MENU
C.E. Credits

The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


AUG 21 - 22 2013

Genetics and Genomics 2013

The theme of this conference is a range of genetics and genomics topics such as RNAi, Next-generation sequencing, Cancer research, Sequencing, Genome-wide association studies GWAS, Epigenetics, Mapping, Exomes, Genomic medicine, Human Genome Structural Variation, Pharmacogenetics, DNA/RNA Purification, Mutations, Translational Genomics, Bioinformatics, Genotyping, Pharmacogenomics, Screening, Cloning, Gene Expression, Phenotyping, Transcription, Functional Genomics, Synthetic Biology, Genome Engineering, Immunology, qPCR/Real-Time PCR, PCR, Biomarkers, Stem Cell research, Human Identification, Bioproduction, Molecular Diagnostics and much more. Attendees can earn free CME and CEU Credits.

This event will bring together research scientists, post docs, principal investigators, lab directors and professionals from around the world to learn about recent advances in genetics and genomics. This conference offers an amazing opportunity as it is free to participants, and there will be no out-of-pocket expenses for travel. However, participants will still benefit from interacting with a global community of like-minded colleagues, without leaving the comfort of their office or home.

With the advent of genetic and genomic medicine, health care providers will benefit from attending this conference and gain knowledge including the understanding of genetic testing, how to calculate risk and when to refer a patient to a genetic specialist, how the application of genomics will be key to effective prevention and management of many of the most important health-care issues. They will learn skills including the ability to communicate genetic information, how to manage family dynamics, become up to date on tools that are available to help the health-care professionals convey complex genetic information to patients.

This program will help to convey to health care practitioners that genetics and genomics are qualitatively different from all other topics because it underlies all of pathophysiology, and is therefore the fundamental science of health and disease.

Conference participants will be able to:
 

  • Attend interactive live streaming video sessions
  • Have their questions answered in real-time by industry experts
  • Chat live with peers and speakers
  • Browse a virtual exhibit floor for solution providers
  • Earn free CME and CEU continuing educationn credits


No crowded airports, delayed flights or expensive hotel rooms, but still the look and feel of a first-rate conference with world renowned experts. Participants also benefit from the fact that experts and vendors are more accessible, no more waiting in line to speak to someone. Think it is too good to be true? Checkout the venue and become a believer.


Speakers
  • Chief of Scientific Intelligence, Director of Molecular Oncology, John Wayne Cancer Institute
  • Associate Professor (Clinical) of Pathology, Division Medical Director, Genetics, Co-Program Director, Clinical Genetics Fellowship Program, Program Director, Molecular Genetics Fellowship Pr
  • Director Bioinformatics, Children's Hospital of Philadelphia, University of Pennsylvania
  • Director of Social Sciences & Bioethics, Assistant Professor, Scripps Translational Science Institute, Scripps Health & The Scripps Research Institute
  • CEO, CSO and Co-Founder, AllSeq, Inc.
  • Assistant Professor of Bioengineering at Stanford, and President of The BioBricks Foundation
  • Chief Scientific Officer, AugureX Life Sciences Corp
  • Assistant Professor, Assistant Investigator, Abramson Family Cancer Research Institute, University of Pennsylvania Medicine
  • Professor of Laboratory Medicine, Mayo Clinic
  • Head of Molecular Microbiology Unit- Molecular Biology, Jewish General Hospital - McGill University
  • Head, Fungal Genomics Program, US Department of Energy Joint Genome Institute
  • Program director for FarGen, Faroe Islands Ministry of Health
  • Senior Manager, NGS Applications, DNASTAR
  • Investigator, Howard Hughes Medical Institute, Professor of Biochemistry, Adjunct Professor of Genome Sciences, Physics, Computer Science, Chemical Engineering, and Bioengineering, University
  • Professor, Cancer & Stem Cell Biology Pgm, Duke-NUS Graduate Medical School Singapore, Sr. Group Leader, Genome Institute of Singapore, Program Leader, Genomic Oncology, Cancer Science In
  • Director, Division of Genomic Technologies, RIKEN Center for Life Science Technologies
  • Associate Director for Science and Technology, Office of In Vitro Diagnostics and Radiological Health (OIR), CDRH, U.S. Food and Drug Administration
  • Founder, President, CEO, TED Fellow, Rare Genomics Institute Washington University in St. Louis
  • Professor of Computational Biology and Bioinformatics, Chair of the Department of Biostatistics, Harvard University, Dana-Farber Cancer Institute
  • Chief Medical Officer, Life Technologies
  • Principle Investigator, Genome Laboratory, Tel Aviv University
  • Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University
  • Associate Professor, Department of Pathology, University of Utah, Medical Director, Molecular Genetics and Genomics ARUP Laboratories
  • Founding Director of the Personalized Medicine Program and Human and Molecular Genetics Center, Warren P. Knowles Chair of Genetics, Professor, Department of Physiology & Pediatrics, Medi
  • Clinical Chemistry Postdoctoral Fellow, University of Chicago
  • Executive Director, Garvan Institute of Medical Research, Conjoint Professor in the St Vincent's Hospital Clinical School and the Faculty of Medicine, at the University of New South Wale
  • Head, Kinghorn Centre for Clinical Genomics, Garvan Institute; CEO, Genome.One
  • Professor, Director, Infectious Diseases Program, J. Craig Venter Institute (JCVI)
  • Professor and Chair, Department of Genetics, Director, Heflin Center for Genomic Sciences, UAB
  • Assistant Professor in the Department of Pathology, Research Scientist, Memorial Sloan-Kettering Cancer Center
  • Professor and Chair, Genetics, Director, Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine
  • Associate Director for Population Sciences, Professor of Community and Family Medicine at the Geisel School of Medicine, Norris Cotton Cancer Center, Dartmouth College
  • Co-director, Pharmacogenomics and Genetics Laboratory, Co-director, Cardiovascular Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic
  • Instructor of Pathology, BWH and Harvard Medical School, Assistant Laboratory Director and Senior IS Domain Specialist Laboratory for Molecular Medicine, Partners HealthCare Center for Perso
  • Professor of Genetics, Director of the Center for Computational Genetics, Harvard Medical School
  • Distinguished Research Scientist, Autodesk Inc., Faculty, Singularity University
  • Laboratory Director, TessArae, LLC
  • Alisa Jackson, Moderator, Beckman Coulter, Inc. Zach Smith, MS, Project Scientist, The Center for Genomics and Bioinformatics, Indiana University Mary Blair, Senior Application Scientist,
  • Chief Scientific Officer, Sequenom
  • Principal Investigator, Andria and Paul Heafy Family Fellow, MIT Whitehead Institute for Biomedical Research
  • Assistant Professor, Department of Systems & Computational Biology, Assistant Professor, Department of Epidemiology & Population Health, Albert Einstein College of Medicine
  • Assistant Professor at the University of Massachusetts Medical School, Program Chair for the Bioinformatics Program, Instructor in the Rabb School of Continuing Studies, Division of Graduate
  • Chief Scientific Officer, CardioDx, Inc.
  • Chief Executive Officer, Claritas Genomics
  • Director, Institute for Aging Research, Ingeborg and Ira Leon Rennert Chair in Aging Research, Professor, Department of Medicine (Endocrinology), Professor, Department of Genetics, Albert Ein
  • Director of Molecular BiologyResearch, Reproductive Medicine Associatesof New Jersey, Associate Professor, Department of Obstetrics, Gynecology,and Reproductive Sciences, UMDNJ-Robert Wood Jo
  • CEO and Founder, IncellDx Inc
  • Associate Professor of Neurobiology, Scripps Institute
  • Assistant Professor, Primary Faculty for the Program in Genomics and Ethics, Medical College of Wisconsin
  • President, Chief Executive Officer and Chief Scientific Officer, Professor of Medicine, Director, Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute
  • Professor, Department of Pathology, Associate Director, Clinical Pathology Laboratories, University of Michigan Health System

Show Resources
You May Also Like
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
JUN 16, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUN 16, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Mass Spectrometry has come a long way over the years and has brought powerful analytical capability to a wide range of applications. Behind every powerful mass spec is a powerful mind workin...
SEP 08, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 08, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 1st Annua...
MAR 24, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
MAR 24, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is pleased to announce the 4th Annual 2021 Cannabis Sciences Virtual Event . LabRoots will host the event on March 24, 2021. The Cannabis Sciences planning committee will be plannin...
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to announce our 9th Annual Genetics Virtual Week held on April 20-22, 2021! Genetics Virtual Week 2021 will offer a multi-day content-rich program combining stellar exper...
SEP 23, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 23, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots and the Cell Biology Planning Committee are please to announce the 4th Annual Cell Biology Virtual Event, providing an opportunity to discuss recent discoveries in biological researc...
Agenda
  • AUG 22, 2013 5:00 PM PDT
    Dave S Hoon, PhD
    Chief of Scientific Intelligence, Director of Molecular Oncology, John Wayne Cancer Institute
  • AUG 22, 2013 5:00 PM PDT
    Patrick Tan, MD, PhD
    Professor, Cancer & Stem Cell Biology Pgm, Duke-NUS Graduate Medical School Singapore, Sr. Group Leader, Genome Institute of Singapore, Program Leader, Genomic Oncology, Cancer Science In
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 4:00 PM PDT
    Piero Carninci, PhD
    Director, Division of Genomic Technologies, RIKEN Center for Life Science Technologies
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 3:00 PM PDT
    Živana Težak, PhD
    Associate Director for Science and Technology, Office of In Vitro Diagnostics and Radiological Health (OIR), CDRH, U.S. Food and Drug Administration
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 3:00 PM PDT
    C Jimmy Lin, MD, PhD, MHS
    Founder, President, CEO, TED Fellow, Rare Genomics Institute Washington University in St. Louis
  • AUG 22, 2013 2:00 PM PDT
    John Quackenbush, PhD
    Professor of Computational Biology and Bioinformatics, Chair of the Department of Biostatistics, Harvard University, Dana-Farber Cancer Institute
  • AUG 22, 2013 2:00 PM PDT
    Paul Billings, MD, PhD
    Chief Medical Officer, Life Technologies
  • AUG 22, 2013 1:00 PM PDT
    Noam Shomron, PhD
    Principle Investigator, Genome Laboratory, Tel Aviv University
  • AUG 22, 2013 1:00 PM PDT
    Kenneth Buetow, PhD, FACMI
    Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University
  • AUG 22, 2013 12:00 PM PDT
    Pinar Bayrak-Toydemir, MD, PhD
    Associate Professor, Department of Pathology, University of Utah, Medical Director, Molecular Genetics and Genomics ARUP Laboratories
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 12:00 PM PDT
    Howard J Jacob, PhD
    Founding Director of the Personalized Medicine Program and Human and Molecular Genetics Center, Warren P. Knowles Chair of Genetics, Professor, Department of Physiology & Pediatrics, Medi
  • AUG 22, 2013 11:00 AM PDT
    David Baker, PhD
    Investigator, Howard Hughes Medical Institute, Professor of Biochemistry, Adjunct Professor of Genome Sciences, Physics, Computer Science, Chemical Engineering, and Bioengineering, University
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 10:00 AM PDT
    Elaine Lyon, PhD
    Associate Professor (Clinical) of Pathology, Division Medical Director, Genetics, Co-Program Director, Clinical Genetics Fellowship Program, Program Director, Molecular Genetics Fellowship Pr
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 10:00 AM PDT
    Bogi Eliasen, MSc
    Program director for FarGen, Faroe Islands Ministry of Health
  • AUG 22, 2013 10:00 AM PDT
    Matthew Keyser, MS
    Senior Manager, NGS Applications, DNASTAR
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 9:00 AM PDT
    Deanne Taylor, MS, PhD
    Director Bioinformatics, Children's Hospital of Philadelphia, University of Pennsylvania
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 9:00 AM PDT
    Shawn Baker, PhD
    CEO, CSO and Co-Founder, AllSeq, Inc.
  • AUG 22, 2013 9:00 AM PDT
    Cinnamon S Bloss, PhD
    Director of Social Sciences & Bioethics, Assistant Professor, Scripps Translational Science Institute, Scripps Health & The Scripps Research Institute
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 8:00 AM PDT
    Drew Endy, PhD
    Assistant Professor of Bioengineering at Stanford, and President of The BioBricks Foundation
  • AUG 22, 2013 7:00 AM PDT
    Kathryn E Wellen, PhD
    Assistant Professor, Assistant Investigator, Abramson Family Cancer Research Institute, University of Pennsylvania Medicine
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 7:00 AM PDT
    Anthony Marotta, PhD
    Chief Scientific Officer, AugureX Life Sciences Corp
  • AUG 22, 2013 7:00 AM PDT
    Thomas P Moyer, PhD
    Professor of Laboratory Medicine, Mayo Clinic
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 5:00 PM PDT
    Igor Grigoriev, PhD
    Head, Fungal Genomics Program, US Department of Energy Joint Genome Institute
  • AUG 21, 2013 5:00 PM PDT
    Ivan Brukner, PhD
    Head of Molecular Microbiology Unit- Molecular Biology, Jewish General Hospital - McGill University
  • AUG 21, 2013 4:00 PM PDT
    Edward Ki Yun Leung, PhD
    Clinical Chemistry Postdoctoral Fellow, University of Chicago
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 4:00 PM PDT
    Marcel Dinger, PhD
    Head, Kinghorn Centre for Clinical Genomics, Garvan Institute; CEO, Genome.One
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 4:00 PM PDT
    John Mattick, PhD,AO, FAA, FRCPA
    Executive Director, Garvan Institute of Medical Research, Conjoint Professor in the St Vincent's Hospital Clinical School and the Faculty of Medicine, at the University of New South Wale
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 3:00 PM PDT
    Steven Rosenberg, PhD
    Chief Scientific Officer, CardioDx, Inc.
  • AUG 21, 2013 3:00 PM PDT
    Daniel Caffrey, PhD
    Assistant Professor at the University of Massachusetts Medical School, Program Chair for the Bioinformatics Program, Instructor in the Rabb School of Continuing Studies, Division of Graduate
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 3:00 PM PDT
    Jessica C. Mar, PhD
    Assistant Professor, Department of Systems & Computational Biology, Assistant Professor, Department of Epidemiology & Population Health, Albert Einstein College of Medicine
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 2:00 PM PDT
    Patrice Milos, PhD
    Chief Executive Officer, Claritas Genomics
  • AUG 21, 2013 2:00 PM PDT
    Nathan R Treff, PhD
    Director of Molecular BiologyResearch, Reproductive Medicine Associatesof New Jersey, Associate Professor, Department of Obstetrics, Gynecology,and Reproductive Sciences, UMDNJ-Robert Wood Jo
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 2:00 PM PDT
    Nir Barzilai, MD
    Director, Institute for Aging Research, Ingeborg and Ira Leon Rennert Chair in Aging Research, Professor, Department of Medicine (Endocrinology), Professor, Department of Genetics, Albert Ein
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 1:00 PM PDT
    Bruce K Patterson, MD
    CEO and Founder, IncellDx Inc
  • AUG 21, 2013 1:00 PM PDT
    Vincent P Mauro, PhD
    Associate Professor of Neurobiology, Scripps Institute
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 1:00 PM PDT
    Kimberly Strong, PhD
    Assistant Professor, Primary Faculty for the Program in Genomics and Ethics, Medical College of Wisconsin
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 12:00 PM PDT
    Robert Roberts, MD, FRCPC, MACC, LLD (Hon.)
    President, Chief Executive Officer and Chief Scientific Officer, Professor of Medicine, Director, Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 12:00 PM PDT
    Yaniv Erlich, PhD
    Principal Investigator, Andria and Paul Heafy Family Fellow, MIT Whitehead Institute for Biomedical Research
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 12:00 PM PDT
    Charles Cantor, PhD
    Chief Scientific Officer, Sequenom
  • AUG 21, 2013 11:00 AM PDT
    Alisa Jackson, Zach Smith, Mary Blair, Dave Delano
    Alisa Jackson, Moderator, Beckman Coulter, Inc. Zach Smith, MS, Project Scientist, The Center for Genomics and Bioinformatics, Indiana University Mary Blair, Senior Application Scientist,
  • AUG 21, 2013 10:00 AM PDT
    William C Nierman, PhD
    Professor, Director, Infectious Diseases Program, J. Craig Venter Institute (JCVI)
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 10:00 AM PDT
    Michael F Berger, PhD
    Assistant Professor in the Department of Pathology, Research Scientist, Memorial Sloan-Kettering Cancer Center
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 10:00 AM PDT
    Bruce R. Korf, MD, PhD
    Professor and Chair, Department of Genetics, Director, Heflin Center for Genomic Sciences, UAB
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 9:00 AM PDT
    Michael Snyder, PhD
    Professor and Chair, Genetics, Director, Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine
  • AUG 21, 2013 8:00 AM PDT
    Linnea Baudhuin, PhD, DABMG
    Co-director, Pharmacogenomics and Genetics Laboratory, Co-director, Cardiovascular Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 8:00 AM PDT
    Matthew Lebo, PhD, FACMG
    Instructor of Pathology, BWH and Harvard Medical School, Assistant Laboratory Director and Senior IS Domain Specialist Laboratory for Molecular Medicine, Partners HealthCare Center for Perso
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 8:00 AM PDT
    Christopher I Amos, PhD
    Associate Director for Population Sciences, Professor of Community and Family Medicine at the Geisel School of Medicine, Norris Cotton Cancer Center, Dartmouth College
  • AUG 21, 2013 7:00 AM PDT
    George Church, PhD
    Professor of Genetics, Director of the Center for Computational Genetics, Harvard Medical School
  • AUG 21, 2013 6:00 AM PDT
    David F Keren, MD
    Professor, Department of Pathology, Associate Director, Clinical Pathology Laboratories, University of Michigan Health System
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 6:00 AM PDT
    Agnieszka Lichanska, PhD
    Laboratory Director, TessArae, LLC
  • AUG 21, 2013 6:00 AM PDT
    Andrew Hessel, MSc
    Distinguished Research Scientist, Autodesk Inc., Faculty, Singularity University
  • AUG 21, 2013 6:00 AM PDT
    David F Keren, MD
    Professor, Department of Pathology, Associate Director, Clinical Pathology Laboratories, University of Michigan Health System
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 6:00 AM PDT
    Agnieszka Lichanska, PhD
    Laboratory Director, TessArae, LLC
  • AUG 21, 2013 6:00 AM PDT
    Andrew Hessel, MSc
    Distinguished Research Scientist, Autodesk Inc., Faculty, Singularity University
  • AUG 21, 2013 7:00 AM PDT
    George Church, PhD
    Professor of Genetics, Director of the Center for Computational Genetics, Harvard Medical School
  • AUG 21, 2013 8:00 AM PDT
    Matthew Lebo, PhD, FACMG
    Instructor of Pathology, BWH and Harvard Medical School, Assistant Laboratory Director and Senior IS Domain Specialist Laboratory for Molecular Medicine, Partners HealthCare Center for Perso
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 8:00 AM PDT
    Linnea Baudhuin, PhD, DABMG
    Co-director, Pharmacogenomics and Genetics Laboratory, Co-director, Cardiovascular Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 8:00 AM PDT
    Christopher I Amos, PhD
    Associate Director for Population Sciences, Professor of Community and Family Medicine at the Geisel School of Medicine, Norris Cotton Cancer Center, Dartmouth College
  • AUG 21, 2013 9:00 AM PDT
    Michael Snyder, PhD
    Professor and Chair, Genetics, Director, Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine
  • AUG 21, 2013 10:00 AM PDT
    Michael F Berger, PhD
    Assistant Professor in the Department of Pathology, Research Scientist, Memorial Sloan-Kettering Cancer Center
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 10:00 AM PDT
    Bruce R. Korf, MD, PhD
    Professor and Chair, Department of Genetics, Director, Heflin Center for Genomic Sciences, UAB
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 10:00 AM PDT
    William C Nierman, PhD
    Professor, Director, Infectious Diseases Program, J. Craig Venter Institute (JCVI)
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 11:00 AM PDT
    Alisa Jackson, Zach Smith, Mary Blair, Dave Delano
    Alisa Jackson, Moderator, Beckman Coulter, Inc. Zach Smith, MS, Project Scientist, The Center for Genomics and Bioinformatics, Indiana University Mary Blair, Senior Application Scientist,
  • AUG 21, 2013 12:00 PM PDT
    Charles Cantor, PhD
    Chief Scientific Officer, Sequenom
  • AUG 21, 2013 12:00 PM PDT
    Yaniv Erlich, PhD
    Principal Investigator, Andria and Paul Heafy Family Fellow, MIT Whitehead Institute for Biomedical Research
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 12:00 PM PDT
    Robert Roberts, MD, FRCPC, MACC, LLD (Hon.)
    President, Chief Executive Officer and Chief Scientific Officer, Professor of Medicine, Director, Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 1:00 PM PDT
    Kimberly Strong, PhD
    Assistant Professor, Primary Faculty for the Program in Genomics and Ethics, Medical College of Wisconsin
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 1:00 PM PDT
    Vincent P Mauro, PhD
    Associate Professor of Neurobiology, Scripps Institute
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 1:00 PM PDT
    Bruce K Patterson, MD
    CEO and Founder, IncellDx Inc
  • AUG 21, 2013 2:00 PM PDT
    Nathan R Treff, PhD
    Director of Molecular BiologyResearch, Reproductive Medicine Associatesof New Jersey, Associate Professor, Department of Obstetrics, Gynecology,and Reproductive Sciences, UMDNJ-Robert Wood Jo
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 2:00 PM PDT
    Nir Barzilai, MD
    Director, Institute for Aging Research, Ingeborg and Ira Leon Rennert Chair in Aging Research, Professor, Department of Medicine (Endocrinology), Professor, Department of Genetics, Albert Ein
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 2:00 PM PDT
    Patrice Milos, PhD
    Chief Executive Officer, Claritas Genomics
  • AUG 21, 2013 3:00 PM PDT
    Steven Rosenberg, PhD
    Chief Scientific Officer, CardioDx, Inc.
  • AUG 21, 2013 3:00 PM PDT
    Daniel Caffrey, PhD
    Assistant Professor at the University of Massachusetts Medical School, Program Chair for the Bioinformatics Program, Instructor in the Rabb School of Continuing Studies, Division of Graduate
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 3:00 PM PDT
    Jessica C. Mar, PhD
    Assistant Professor, Department of Systems & Computational Biology, Assistant Professor, Department of Epidemiology & Population Health, Albert Einstein College of Medicine
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 4:00 PM PDT
    Marcel Dinger, PhD
    Head, Kinghorn Centre for Clinical Genomics, Garvan Institute; CEO, Genome.One
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 4:00 PM PDT
    John Mattick, PhD,AO, FAA, FRCPA
    Executive Director, Garvan Institute of Medical Research, Conjoint Professor in the St Vincent's Hospital Clinical School and the Faculty of Medicine, at the University of New South Wale
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 4:00 PM PDT
    Edward Ki Yun Leung, PhD
    Clinical Chemistry Postdoctoral Fellow, University of Chicago
    SEE ABSTRACT | Continuing Education: CE
  • AUG 21, 2013 5:00 PM PDT
    Igor Grigoriev, PhD
    Head, Fungal Genomics Program, US Department of Energy Joint Genome Institute
  • AUG 21, 2013 5:00 PM PDT
    Ivan Brukner, PhD
    Head of Molecular Microbiology Unit- Molecular Biology, Jewish General Hospital - McGill University
  • AUG 22, 2013 7:00 AM PDT
    Thomas P Moyer, PhD
    Professor of Laboratory Medicine, Mayo Clinic
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 7:00 AM PDT
    Anthony Marotta, PhD
    Chief Scientific Officer, AugureX Life Sciences Corp
  • AUG 22, 2013 7:00 AM PDT
    Kathryn E Wellen, PhD
    Assistant Professor, Assistant Investigator, Abramson Family Cancer Research Institute, University of Pennsylvania Medicine
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 8:00 AM PDT
    Drew Endy, PhD
    Assistant Professor of Bioengineering at Stanford, and President of The BioBricks Foundation
  • AUG 22, 2013 9:00 AM PDT
    Shawn Baker, PhD
    CEO, CSO and Co-Founder, AllSeq, Inc.
  • AUG 22, 2013 9:00 AM PDT
    Cinnamon S Bloss, PhD
    Director of Social Sciences & Bioethics, Assistant Professor, Scripps Translational Science Institute, Scripps Health & The Scripps Research Institute
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 9:00 AM PDT
    Deanne Taylor, MS, PhD
    Director Bioinformatics, Children's Hospital of Philadelphia, University of Pennsylvania
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 10:00 AM PDT
    Elaine Lyon, PhD
    Associate Professor (Clinical) of Pathology, Division Medical Director, Genetics, Co-Program Director, Clinical Genetics Fellowship Program, Program Director, Molecular Genetics Fellowship Pr
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 10:00 AM PDT
    Bogi Eliasen, MSc
    Program director for FarGen, Faroe Islands Ministry of Health
  • AUG 22, 2013 10:00 AM PDT
    Matthew Keyser, MS
    Senior Manager, NGS Applications, DNASTAR
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 11:00 AM PDT
    David Baker, PhD
    Investigator, Howard Hughes Medical Institute, Professor of Biochemistry, Adjunct Professor of Genome Sciences, Physics, Computer Science, Chemical Engineering, and Bioengineering, University
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 12:00 PM PDT
    Howard J Jacob, PhD
    Founding Director of the Personalized Medicine Program and Human and Molecular Genetics Center, Warren P. Knowles Chair of Genetics, Professor, Department of Physiology & Pediatrics, Medi
  • AUG 22, 2013 12:00 PM PDT
    Pinar Bayrak-Toydemir, MD, PhD
    Associate Professor, Department of Pathology, University of Utah, Medical Director, Molecular Genetics and Genomics ARUP Laboratories
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 1:00 PM PDT
    Kenneth Buetow, PhD, FACMI
    Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University
  • AUG 22, 2013 1:00 PM PDT
    Noam Shomron, PhD
    Principle Investigator, Genome Laboratory, Tel Aviv University
  • AUG 22, 2013 2:00 PM PDT
    Paul Billings, MD, PhD
    Chief Medical Officer, Life Technologies
  • AUG 22, 2013 2:00 PM PDT
    John Quackenbush, PhD
    Professor of Computational Biology and Bioinformatics, Chair of the Department of Biostatistics, Harvard University, Dana-Farber Cancer Institute
  • AUG 22, 2013 3:00 PM PDT
    C Jimmy Lin, MD, PhD, MHS
    Founder, President, CEO, TED Fellow, Rare Genomics Institute Washington University in St. Louis
  • AUG 22, 2013 3:00 PM PDT
    Živana Težak, PhD
    Associate Director for Science and Technology, Office of In Vitro Diagnostics and Radiological Health (OIR), CDRH, U.S. Food and Drug Administration
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 4:00 PM PDT
    Piero Carninci, PhD
    Director, Division of Genomic Technologies, RIKEN Center for Life Science Technologies
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 5:00 PM PDT
    Patrick Tan, MD, PhD
    Professor, Cancer & Stem Cell Biology Pgm, Duke-NUS Graduate Medical School Singapore, Sr. Group Leader, Genome Institute of Singapore, Program Leader, Genomic Oncology, Cancer Science In
    SEE ABSTRACT | Continuing Education: CE
  • AUG 22, 2013 5:00 PM PDT
    Dave S Hoon, PhD
    Chief of Scientific Intelligence, Director of Molecular Oncology, John Wayne Cancer Institute
Speakers

  • Dave S Hoon, PhD
    Chief of Scientific Intelligence, Director of Molecular Oncology, John Wayne Cancer Institute
  • Elaine Lyon, PhD
    Associate Professor (Clinical) of Pathology, Division Medical Director, Genetics, Co-Program Director, Clinical Genetics Fellowship Program, Program Director, Molecular Genetics Fellowship Pr
    Biography
      Dr. Lyon is the medical director of the Genetics Division, co-medical director of Pharmacogenomics, and co-director of the Molecular Genetics Fellowship Program at ARUP, and an associate professor of pathology at the University of Utah School of Medicine. She received her PhD in medical genetics from the University of Alabama at Birmingham and continued with fellowship training in clinical molecular genetics at the University of Utah. Dr. Lyon combines clinical laboratory responsibilities with research and development in human genetics, employing methods for mutation detection by targeted mutation analysis, gene sequencing, gene scanning, exonic-level deletion, and duplications and molecular haplotyping. Dr. Lyon has focused her interest in studies to determine the significance of rare variants and is involved with evaluating and establishing locus-specific databases that combine genetic variants with clinical symptoms.
    • Deanne Taylor, MS, PhD
      Director Bioinformatics, Children's Hospital of Philadelphia, University of Pennsylvania
      Biography
        Deanne Taylor joined DBHI in 2014 as the Bioinformatics Director. Deanne oversees the design, development, and implementation of high performance innovative bioinformatics workflows and provide technical leadership and supervision of a multidisciplinary bioinformatics team at CHOP. Previously, she was Director of Bioinformatics with Reproductive Medicine Associates and Assistant Professor with the Department of Obstetrics, Gynecology and Reproductive Medicine at Rutgers Robert Wood Johnson Medical School. Prior to that she worked for Harvard School of Public Health as a Research Scientist and served several years as the Program Director of the Graduate Program in Bioinformatics at Brandeis University. She also has experience working in the pharmaceutical industry. Deanne obtained her PhD in Biophysics from the University of Michigan, Ann Arbor, and completed a postdoctoral fellowship at Pfizer. Her background is in biophysics, bioinformatics, computational biology and structural biology with emphasis on human genetics and translational medicine. Deanne's main areas of research are in the development of mathematical and computational methods to better understand biological variation and the genetic contribution to disease, coupling clinical information with high-dimensional biomedical data from next-gen sequencing, microarray, PCR, and proteomics experiments.
      • Cinnamon S Bloss, PhD
        Director of Social Sciences & Bioethics, Assistant Professor, Scripps Translational Science Institute, Scripps Health & The Scripps Research Institute
        Biography
          Dr. Bloss is an Assistant Professor, as well as Director of Social Sciences and Bioethics at the Scripps Translational Science Institute. Her research is funded by the National Institutes of Health and is focused on investigating individuals' behavioral and psychological responses to disclosure of personal genomic information. She is the lead researcher on STSI's Scripps Genomic Health Initiative, and her work on this project was recently published in the New England Journal of Medicine and has been highlighted at a number of national and international scientific meetings. She has also presented invited testimony on consumer genomics before the Food and Drug Administration Advisory Panel.   Dr. Bloss' other research interests include developing ways of combining genomics with traditional disease risk factors to make predictions about disease development, progression and response to treatment, as well as designing effective health interventions that leverage genomic information. She also conducts genetic association studies and has several collaborations to investigate the genetic underpinnings of neurological, behavioral, and other health-related phenotypes.   Dr. Bloss received her B.A. in Psychology from Smith College, her Ph.D. in Clinical Psychology from the University of California, San Diego, and completed a predoctoral internship in clinical neuropsychology at the University of Florida. Dr. Bloss completed a post-doctoral fellowship in statistical genetics and genomic medicine at The Scripps Research Institute.
        • Shawn Baker, PhD
          CEO, CSO and Co-Founder, AllSeq, Inc.
          Biography
            Dr. Shawn C. Baker is the Chief Science Officer and co-founder of AllSeq. Having received his Ph.D. at the University of California - Davis, he started his career as a Research Scientist at Illumina when it was a 15-person startup. After spending several years at the bench developing gene expression array products, he transitioned to Product Marketing where he led a team in charge of Illuminas Expression and Regulation sequencing portfolio. In 2013 Dr. Baker co-founded AllSeq, establishing the only true sequencing marketplace, matching researchers with service providers based on their needs. <br />
          • Drew Endy, PhD
            Assistant Professor of Bioengineering at Stanford, and President of The BioBricks Foundation
            Biography
              Drew Endy developed the world's first "fabless" genetic engineering teaching lab in the new Bioengineering program at Stanford and previously helped start the Biological Engineering major at MIT. His Stanford research team develops genetically encoded computers and redesigns genomes. He co-founded the BioBricks Foundation as a public-benefit charity supporting free-to-use standards and technology that enable the engineering of biology. He co-organized the International Genetically Engineered Machines (iGEM.org) competition, the BIOFAB International Open Facility Advancing Biotechnology (BIOFAB.org), and Gen9, Inc. (Gen9bio.com). He serves on the US Committee on Science Technology and Law and is a new voting member of the US National Science Advisory Board for Biosecurity. He chaired the 2003 Synthetic Biology study as a member of DARPA ISAT, served as an ad hoc member of the US NIH Recombinant DNA Advisor Committee, and co-authored the 2007 "Synthetic Genomics: Options for Governance" report with colleagues from the Center for Strategic & International Studies and the J. Craig Venter Institute. Esquire named Endy one of the 75 most influential people of the 21st century. He lives in Menlo Park CA with his wife and Stanford Bioengineering colleague Prof. Christina Smolke.
            • Anthony Marotta, PhD
              Chief Scientific Officer, AugureX Life Sciences Corp
              Biography
                Anthony serves as the Chief Scientific Officer at Augurex Life Sciences Corp, a company that he co-founded with CEO, Mrs. Norma Biln. Anthony's creativity and business acumen have set him apart from most scientific leaders. Anthony has worked in the life sciences space for 20 years and has consistently created progressive opportunities that have delivered great returns for companies that he has been involved with. He received his PhD from the Faculty of Medicine at the University of British Columbia in Vancouver, Canada.
              • Kathryn E Wellen, PhD
                Assistant Professor, Assistant Investigator, Abramson Family Cancer Research Institute, University of Pennsylvania Medicine
                Biography
                  Dr. Kathryn Wellen received a PhD from Harvard University in 2006 and performed postdoctoral work at the University of Pennsylvania from 2006-2011. In 2011 she joined the Department of Cancer Biology at the University of Pennsylvania as an Assistant Professor. She is a 2012 Pew Scholar in the Biomedical Sciences and is a recipient of a 2012 Forbeck Scholar Award. Her laboratory's research focuses on elucidating links between cellular metabolism and signaling, with a current emphasis on metabolic regulation of the epigenome.
                • Thomas P Moyer, PhD
                  Professor of Laboratory Medicine, Mayo Clinic
                  Biography
                    Thomas P Moyer received a BA in Chemistry from the University of Minnesota in 1970. Following receipt of his undergraduate degree he spent two years in the United State Army Infantry. Upon completing his military service, Moyer entered graduate school at North Dakota State University where he earned the PhD degree in Biochemistry in 1976. He trained at Mayo Clinic as a Fellow in Clinical Chemistry, and joined the medical staff of Mayo Clinic in Rochester, Minnesota in 1979 as a Consultant in the Department of Laboratory Medicine & Pathology. While at Mayo Clinic, Moyer created the Drug Laboratory and lead in the formation of the Nucleotide Polymorphism Laboratory. He was Division Chair of Clinical Biochemistry & Immunology, and served as Vice Chair of the Department of Laboratory Medicine & Pathology and as Senior Vice President of Mayo Medical Laboratories. Dr. Moyer was elected by the medical staff to serve as an Officer of Mayo Clinic in 2000. He has published 108 peer reviewed papers, 123 abstracts, 30 book chapters, and two books. Dr Moyer was also active in the American Association for Clinical Chemistry (AACC) serving in numerous leadership roles, including as President in 2004. He also represented AACC to the International Federation of Clinical Chemistry, serving as a member of the Scientific Division, and a member of the Congress and Conference Division.
                  • Ivan Brukner, PhD
                    Head of Molecular Microbiology Unit- Molecular Biology, Jewish General Hospital - McGill University
                  • Igor Grigoriev, PhD
                    Head, Fungal Genomics Program, US Department of Energy Joint Genome Institute
                    Biography
                      Dr. Grigoriev joined the DOE Joint Genome Institute in 2003 to participate in human genome annotation and lead annotation of over 200 diverse eukaryotic genomes from protists to plants (http://genome.jgi.doe.gov). In 2009 at JGI he started the Fungal Genomics program (http://www.jgi.doe.gov/fungi) to scale up sequencing and analysis of diverse fungi for related to DOE science and applications, which led to large projects like 1000 Fungal Genomes. Dr. Grigoriev organized over 30 genomics workshops and engaged over 2000 researches around the world in genome projects, which resulted in over 50 high-profile publications.
                    • Bogi Eliasen, MSc
                      Program director for FarGen, Faroe Islands Ministry of Health
                      Biography
                        Bogi Eliasen is a knowledge-broker bringing the expertise of all kinds of disciplines together. He is an expert on international politics and law and manages the first nationwide genome sequencing project in the world, FarGen.
                      • Matthew Keyser, MS
                        Senior Manager, NGS Applications, DNASTAR
                        Biography
                          Matthew Keyser is Senior Manager, NGS Applications for DNASTAR, where he has helped scientists address their sequence assembly and analysis challenges for the past seven years. Matts sole focus at DNASTAR is supporting customers in next-gen sequencing applications using DNASTARs broad software toolset. Matt helps customers with their templated and de novo assembly projects, transcriptomes, exomes, metagenomic assemblies, RNA-Seq, ChIP-Seq and numerous other unique experiments. Matt has helped hundreds of scientists optimize their workflows using DNASTARs next-gen software solutions. He has also spoken at numerous conferences and workshops regarding the capabilities of DNASTARs next-gen software tools.
                        • David Baker, PhD
                          Investigator, Howard Hughes Medical Institute, Professor of Biochemistry, Adjunct Professor of Genome Sciences, Physics, Computer Science, Chemical Engineering, and Bioengineering, University
                          Biography
                            The Baker laboratory developed the Rosetta algorithm for ab initio protein structure prediction, which has been extended to a distributed computing project called Rosetta@Home and Foldit. The project aims to produce structural models for protein complexes as well as individual polypeptide chains. The Baker group participates regularly and is recognized for expertise in the CASP structure prediction experiment using ab initio methods, including both manually assisted and automated variants of the Rosetta protocol. Members of the Baker group are also active in the field of protein design; they are recognized as the first group to have designed a protein, known as Top7, with an entirely novel fold. Baker did his graduate work in biochemistry at the University of California, Berkeley in the laboratory of Randy Schekman, where he worked predominantly on protein transport and trafficking in yeast. He did his postdoctoral work with David Agard of University of California, San Francisco. Although well known for development of methods for computational prediction of protein structure and function, Baker is focused on the use of computational methods to drive experimental assessment of biology and therefore the Baker laboratory maintains an active experimental biochemistry group. For his work on protein folding, Baker received the 2008 Sackler International Prize in Biophysics. Baker was elected a Fellow of the American Academy of Arts and Sciences in 2009.
                          • Patrick Tan, MD, PhD
                            Professor, Cancer &amp; Stem Cell Biology Pgm, Duke-NUS Graduate Medical School Singapore, Sr. Group Leader, Genome Institute of Singapore, Program Leader, Genomic Oncology, Cancer Science In
                            Biography
                              Dr. Patrick Tan holds a joint appointment as a Professor at the Duke-NUS Graduate Medical School and Senior Group Leader at the Genome Institute of Singapore. He is also Senior Principal Investigator at the Cancer Science Institute of Singapore, National University of Singapore and Research Associate Professor in the Institute of Genome Sciences and Policy at Duke University, USA. His research focuses on the application of genomics to cancer and infectious disease. He received his B.A. (summa cum laude) from Harvard University and MD PhD degree from Stanford University, where he received the Charles Yanofsky prize for Most Outstanding Graduate Thesis in Physics, Biology or Chemistry. Other honors include the President's Scholarship, Loke Cheng Kim foundation scholarship, Young Scientist Award (A-STAR), Singapore Youth Award (twice), Singhealth Investigator Excellence Award, Han-Mo Koo Memorial Lectureship (Van Andel Research Institute, USA) and Swee Liew Wadsworth Lectureship (NUS). Recently, he received the Chen New Investigator Award from the Human Genome Organization (HUGO), and was elected to the American Society for Clinical Investigation (ASCI). He is a member of the Bioethics Advisory Committee (BAC), a national body that provides advice to the Singapore government on ethical issues related to biomedical research.
                            • Piero Carninci, PhD
                              Director, Division of Genomic Technologies, RIKEN Center for Life Science Technologies
                              Biography
                                Born and Educated in Italy he obtained his doctoral degree at the University of Trieste in 1989. From 1990 to 1995 he developed technologies for DNA extraction and DNA sequencing at Talent, a spin-off biotech. He moved to Japan in 1995 at RIKEN, Tsukuba Life Science center and became tenure researcher in 1997. He has been developing technologies to capture full-length cDNAs, which were used for the construction of the Fantom projects. Between 2008 and 2013, he was a Team and Unit Leader and a Deputy Project Director at the RIKEN Omics Science Center in Yokohama. He has developed technologies to analyze the the transcribed part of the genome (transcriptome), such as the cap-trapper and the CAGE. These technologies have been broadly used in the RIKEN Fantom projects and allowed identifying non-coding RNAs as are the major output of the mammalian genome and providing comprehensive maps of the mammalian promoters. Additionally he developed a miniaturization of CAGE, in order to approach biological problems that for which there is limited amount of starting material. From April in 2013, he is a Director of the Division Genomics Technologies and a Deputy Director of Center for Life Science Technologies, RIKEN. He has published more than 200 papers and book chapters, edited books and is a member of editorial boards of various scientific journals.
                              • Živana Težak, PhD
                                Associate Director for Science and Technology, Office of In Vitro Diagnostics and Radiological Health (OIR), CDRH, U.S. Food and Drug Administration
                                Biography
                                  Živana Težak, Ph.D., is an Associate Director for Science and Technology, Personalized Medicine Staff, in the Office of In Vitro Diagnostic Device (IVD) Evaluation and Safety (OIR), at the Center for Devices and Radiological Health, Food and Drug Administration (FDA). Prior to joining the FDA in 2004, as a scientific reviewer in microbiology, genomics and molecular biology, Dr. Težak worked in biotechnology industry, holding research and development scientist positions in a bioinformatics and array developer company. Dr. Težak received a Ph.D. in Biochemistry/Molecular Biology from Florida State University in 1997. From 1998 to 2001 she was a research fellow at the University of Pittsburgh Medical Center and Children's National Medical Center, Research Center for Genetic Medicine, working on neuromuscular disorders, human genetics, gene therapy, and high-throughput screening technologies. Her work resulted in a number of publications in peer-reviewed journals, book chapters and proceedings. In her current position, Dr. Težak has been leading efforts to develop flexible regulatory policies for novel technology based IVDs, such as chromosomal microarrays and next-generation sequencing, in order to enable their smoother translation into the clinic.
                                • C Jimmy Lin, MD, PhD, MHS
                                  Founder, President, CEO, TED Fellow, Rare Genomics Institute Washington University in St. Louis
                                  Biography
                                    Jimmy Lin, MD, PhD, MHS, is a 2012 TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Partnering with 18 of the top medical institutions, such as Harvard, Yale, Johns Hopkins, and Stanford, RGI helps custom design personalized research projects for diseases so rare that no organization exists to help. Dr. Lin is also a medical school faculty member at the Washington University in St. Louis and led the computational analysis of the first ever exome sequenching studies for any human disease at Johns Hopkins. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in Forbes, Bloomberg, Wall Street Journal, Washington Post, and the Huffington Post.
                                  • John Quackenbush, PhD
                                    Professor of Computational Biology and Bioinformatics, Chair of the Department of Biostatistics, Harvard University, Dana-Farber Cancer Institute
                                    Biography
                                      John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John's PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. He currently directs the Computational Biology and Quantitative Genetics MS program and is PI of the BD2K Training Grant at HSPH. John's research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.
                                    • Paul Billings, MD, PhD
                                      Chief Medical Officer, Life Technologies
                                      Biography
                                        Board certified internist and clinical geneticist Dr. Paul R. Billings serves as Chief Medical Officer, a new position aimed at improving patient care through expanding the use of medically relevant genomic technologies in clinical settings. Dr. Billings brings extensive expertise and clinical experience in the areas of genomics and molecular medicine. Most recently, he served as Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in the Silicon Valley. He currently serves as a member of the United States Department of Health and Human Services Secretary's Advisory Committee on Genetics, Health and Society, where he helps shape policy in the rapidly evolving field of genomic medicine. Dr. Billings has had a distinguished career as a physician and researcher. He has been a founder or chief executive officer of companies involved in genetic and diagnostic medicine, including GeneSage, Omicia and CELLective Dx Corporation. Previously, he was senior vice president for corporate development at Laboratory Corporation of America Holdings (LabCorp). He has held academic appointments at some of the most prestigious universities in the United States, including Harvard Medical School, Stanford School of Medicine and the University of California, Berkeley, and has served as a physician at a number of medical centers throughout the country, including the University of California, San Francisco. He is the author of nearly 200 publications and books on genomic medicine. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology, also from Harvard University.
                                      • Noam Shomron, PhD
                                        Principle Investigator, Genome Laboratory, Tel Aviv University
                                        Biography
                                          Dr. Noam Shomron heads a research team which focuses on the analysis of genomic sequences and gene expression aimed at understanding human diseases. Dr Shomron trained at Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) where he combined high-throughput methods with computational analysis. Dr Shomron joined Tel Aviv University's Medical School in October 2008. Dr Shomron's is highly skilled in deep (next generation) sequencing technologies, in addition to parsing and processing the sequencing output. His strength in the genomic world stems from his extensive experience and knowledge using state-of-the-art methods both experimentally and computationally. Dr Shomron's overall interest and goals lie within seeking a better understanding of the mechanisms leading to disease development. His team seeks innovative solutions to generate a significant impact through translating ideas into clinical reality. Dr Shomron is also the Director of Rare Genomics Institute's Israel branch; co-founder and Scientific Director of the Functional Genomics Laboratory at Tel Aviv University; Editor-in-Chief of ‘Genetics Research' (published by Cambridge University Press); Editor of ‘Deep Sequencing Data Analysis' (a ‘Methods in Molecular Biology' book series published by Springer/Humana Press), Academic Director of BioAbroad.
                                        • Kenneth Buetow, PhD, FACMI
                                          Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University
                                          Biography
                                            Dr. Ken Buetow is a human genetics and genomics researcher who leverages computational tools to understand complex traits such as cancer, liver disease, and obesity. Dr. Buetow currently serves as Director of Computational Sciences and Informatics program for Complex Adaptive Systems at Arizona State University (CAS@ASU) and is a professor in the School of Life Sciences in ASU's College of Liberal Arts and Sciences. CAS@ASU applies systems approaches that leverage ASU's interdisciplinary research strengths to address complex global challenges. The Computational Sciences and Informatics program is developing and applying information technology to collect, connect, and enhance trans-disciplinary knowledge both within ASU and across the broader knowledge-generating ecosystems. CAS@ASU is creating a Next Generation Cyber Capability to address the challenges and opportunities afforded by "Big Data" and the emergence of 4th Paradigm Data Science. This capability brings state-of-the-art computational approaches to CAS@ASU's transdisciplinary, use-inspired research efforts Dr. Buetow previously served as the Director of the Center for Biomedical Informatics and Information Technology within the National Institutes of Health's National Cancer Institute (NCI). In that capacity he initiated and oversaw the NCI's efforts to connect the global cancer community through community-developed, standards-based, interoperable informatics capabilities that enable secure exchange and use of biomedical data. Buetow designed and built one of the largest biomedical computing efforts in the world. He was responsible for coordinating biomedical informatics and information technology at the NCI. The NCI center he led focused on speeding scientific discovery and facilitated translational research by coordinating, developing and deploying biomedical informatics systems, infrastructure, tools and data in support of NCI research initiatives.
                                          • Pinar Bayrak-Toydemir, MD, PhD
                                            Associate Professor, Department of Pathology, University of Utah, Medical Director, Molecular Genetics and Genomics ARUP Laboratories
                                            Biography
                                              Dr. Bayrak-Toydemir is a Medical Director of the Molecular Genetics and Genomics Laboratories at Associated Regional and University Pathologists (ARUP) Laboratories and an Associate Professor of Pathology at the University of Utah, School of Medicine. Dr. Bayrak-Toydemir received her MD from Ankara University School of Medicine in Ankara, Turkey, where she also received her PhD in Human Genetics. Subsequently, she completed her fellowship in Clinical Molecular Genetics at the University of Utah. She is board certified in clinical molecular genetics. Dr. Bayrak-Toydemir has a long term interest in identification of genes that cause various inherited vascular malformations. Specifically, she is interested in hereditary hemorrhagic telangiectasia, capillary malformation-arteriovenous malformation syndrome, and aortopathies. She has extensive experience on both the clinical and research applications of the next generation sequencing technology. Under her leadership Molecular Genetics Laboratory is able to offer a long list of gene panels and exome sequencing, and help to improve patient management in various disorders, by providing a comprehensive evaluation of the underlying genetic background.
                                            • Howard J Jacob, PhD
                                              Founding Director of the Personalized Medicine Program and Human and Molecular Genetics Center, Warren P. Knowles Chair of Genetics, Professor, Department of Physiology &amp; Pediatrics, Medi
                                            • Edward Ki Yun Leung, PhD
                                              Clinical Chemistry Postdoctoral Fellow, University of Chicago
                                              Biography
                                                Born and raised in Vancouver, British Columbia, Canada. I received my Bachelor of Science and my Doctor of Philosophy from the Department of Molecular Biology and Biochemistry at Simon Fraser University. I studied the photochemistry and reduction-oxidation chemistry of nucleic acids with Dr. Dipankar Sen. I was a postdoctoral fellow for three years with Dr. Joseph Piccirilli from the Department of Biochemistry and Molecular Biology at the University of Chicago and studied RNA structural biology using phage-display technology and crystallography. For the past two years, I am in the clinical chemistry postdoctoral fellow at the University of Chicago Medicine, a ComACC certified training program under the directorship of Dr. Jerry Yeo. My research interest is in personalized medicine. My research interest is in personalized medicine. I am interested in developing and using mass spectrometry to study an observed phenotype (ie. protein levels, protein post-translational modifications, and active drugs and/or its metabolites) and next-generation sequencing to study the corresponding genotype. By combining genetic and phenotypic data, a more well-rounded and complete understanding of personalized medicine can be achieved.
                                              • John Mattick, PhD,AO, FAA, FRCPA
                                                Executive Director, Garvan Institute of Medical Research, Conjoint Professor in the St Vincent's Hospital Clinical School and the Faculty of Medicine, at the University of New South Wale
                                                Biography
                                                  John joined the Garvan Institute as the Executive Director in January 2012. He has made a significant contribution to the understanding of genetics and genomics through his farsighted theories on 'junk' DNA, the large non-coding sections of the human genome that do not code for proteins. Most recently John was the Professor of Molecular Biology and NHMRC Australia Fellow at the Institute for Molecular Bioscience, University of Queensland. John was educated at St Patrick's College Strathfield, the University of Sydney and Monash University, where he obtained his PhD. He has subsequently worked at Baylor College of Medicine in Houston, the CSIRO Division of Molecular Biology in Sydney, and the University of Queensland, where he was based from 1988-2011. He has also spent research periods at the Universities of Cambridge, Oxford, Cologne and Strasbourg. He was Foundation Director of the Australian Genome Research Facility and the Institute for Molecular Bioscience.
                                                • Marcel Dinger, PhD
                                                  Head, Kinghorn Centre for Clinical Genomics, Garvan Institute; CEO, Genome.One
                                                  Biography
                                                    Marcel Dinger is the Founding CEO of Genome.One, Head of the Kinghorn Centre for Clinical Genomics (KCCG) at the Garvan Institute of Medical Research and conjoint Associate Professor at UNSW Australia. Genome.One is a world-class clinical genomics service and develops specialist software and analytics solutions to enable precision healthcare worldwide. Genome.One was one of the first companies in the world to implement the HiSeq X Ten genome sequencing platform, which has capacity to sequence 18,000 human genomes per year, and provide a disease diagnostics service based on whole genome sequencing. He has worked in bioinformatics and genomics since 1998 in both commercial and academic capacities. He was awarded his PhD in 2003 from the University of Waikato in New Zealand, has published >90 papers attracting more than 10,000 citations, and is recipient of several highly competitive awards and fellowships. He is also a founder of two other successful start-up companies. In 2016, Marcel was admitted as a Fellow into the Faculty of Sciences of the Royal College of Pathologists of Australiasia and is a Graduate of the Australian Institute of Company Directors.
                                                  • William C Nierman, PhD
                                                    Professor, Director, Infectious Diseases Program, J. Craig Venter Institute (JCVI)
                                                    Biography
                                                      Dr. William Nierman is the Director of the Infectious Disease Program at the J. Craig Venter Institute (JCVI). He is also a Professor the George Washington University School of Medicine and has taught Human Genetics at The Johns Hopkins University. He received his BS degree from the US Naval Academy and his PhD degree from the University of California, Berkeley. Dr. Nierman has broad experience in microbial pathogen genomics. His research focus is the genomic and functional analysis of two the levels of pathogen interaction with the human host, that caused by severe acute disease-causing bacterial pathogens, and that caused by fungi that can cause disease only in an immune-system-compromised host. Burkholderia mallei and Burkholderia pseudomallei are severe bacterial pathogens that cause difficult to diagnose but very life threatening diseases, glanders and melioidosis. At the other end of the pathogenicity scale are Aspergillus and Penicillium fungal pathogens which cause invasive or systemic disease in immune compromised or immune suppressed human hosts. Management of the disease in both classes of infections is becoming increasingly compromised by the rapid evolution of drug resistance in the pathogens. Both groups of organisms pose serious public health issues in both developed and in developing countries.
                                                    • Bruce R. Korf, MD, PhD
                                                      Professor and Chair, Department of Genetics, Director, Heflin Center for Genomic Sciences, UAB
                                                      Biography
                                                        Dr. Korf is the Chief Genomics Officer, UAB Medicine, Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics, Professor of Genetics, Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine, Associate Director for Rare Diseases, Hugh Kaul Personalized Medicine Institute and editor-in-chief of the American Journal of Human Genetics. He is a medical geneticist, pediatrician, and child neurologist, certified by the American Board of Medical Genetics and Genomics (clinical genetics, clinical cytogenetics, and clinical molecular genetics), American Board of Pediatrics, and American Board of Psychiatry and Neurology (child neurology). Dr. Korf is past president of the Association of Professors of Human and Medical Genetics, past president of the American College of Medical Genetics and Genomics, and current president of the ACMG Foundation for Genetic and Genomic Medicine. He has served on the Board of Scientific Counselors of the National Cancer Institute and the National Human Genome Research Institute at the NIH. His major research interests are molecular diagnosis of genetic disorders and the natural history, genetics, and treatment of neurofibromatosis. He serves as principal investigator of the Department of Defense funded Neurofibromatosis Clinical Trials Consortium, the Alabama Genomic Health Initiative, and the Southern All of Us Network. He is co-author of Human Genetics and Genomics (medical student textbook, now in fourth edition), Medical Genetics at a Glance (medical student textbook (now in third edition), Emery and Rimoin's Principles and Practice of Medical Genetics (now in 6th edition), and Current Protocols in Human Genetics.
                                                      • Michael F Berger, PhD
                                                        Assistant Professor in the Department of Pathology, Research Scientist, Memorial Sloan-Kettering Cancer Center
                                                        Biography
                                                          Michael Berger, PhD is an Assistant Attending in the Department of Pathology and an Affiliate Member of the Human Oncology and Pathogenesis Program, with expertise in cancer genomics and computational biology. His research focuses on the enumeration of the spectrum of genetic mutations in human tumors in order to identify biomarkers of cancer progression and drug response. Dr. Berger joined the MSKCC faculty in October 2010 after working as a research scientist and computational biologist in the Cancer Program at the Broad Institute of Harvard and MIT. At the Broad, he served as the project leader and primary data analyst for numerous efforts employing massively parallel "next generation" sequencing to characterize genetic mutations in a range of cancers. He now runs an independent research laboratory at MSKCC that is developing methods to reliably and accurately profile clinical specimens for cancer-related DNA mutations and copy number alterations. His laboratory is engaged in many collaborations with clinical and translational investigators to discover significant oncogenic mutations in rare or understudied tumor types and identify genomic biomarkers exhibiting correlations with clinical outcomes and therapeutic response. He is also working closely with the CLIA compliant Diagnostic Molecular Pathology Laboratory to build a robust profiling pipeline and analytical framework for use in real-time patient management. Dr. Berger received his Bachelor's Degree in Physics at Princeton University and his Ph.D. in Biophysics at Harvard University.
                                                        • Michael Snyder, PhD
                                                          Professor and Chair, Genetics, Director, Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine
                                                          Biography
                                                            Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of-the-art "omics" technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Technologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.
                                                          • Christopher I Amos, PhD
                                                            Associate Director for Population Sciences, Professor of Community and Family Medicine at the Geisel School of Medicine, Norris Cotton Cancer Center, Dartmouth College
                                                            Biography
                                                              Dr. Christopher Amos received his M.S. and Ph.D. degrees in 1985 and 1988 from the Louisiana State University Medical Center in New Orleans from the Department of Biometry and Genetics. In his graduate studies he developed novel approaches for conducting genetic linkage analysis for multivariate data and in extended families. Subsequently, Dr. Amos completed training in Medical Genetics through the Inter-institute training program in Genetics at the NIH (1992), where he also completed postdoctoral training in the Family Studies Section of the Environmental Epidemiology Branch at the National Cancer Institute. During this period (1988-1992), he studied inheritance patterns of breast and ovarian cancers, publishing seminal papers in the Journal of the American Medical Association and the Journal of the National Cancer Institute. He also developed a novel and widely cited approach for linkage analysis that was published in the American Journal of Human Genetics in 1994(PMID:8116623, 787 citations). He has authored or coauthored 548 peer reviewed papers, 19 reviews or book chapters, 2 books and has an H index of 104 with 43,170 citations. His work is funded by 11 current and 2 approved pending P01 grants from NIH (on one he serves as communicating PI). He has served as PI, multiple PI or core leader on 25 funded grants (including R01, U01, P01, U19, P20, P30 and T32 grants from NIH and ACS grants) and coinvestgator on an additional than 14 grants. In 1992 he was recruited to the M.D. Anderson Cancer Center where he joined the Department of Epidemiology and established the Section of Computational and Genetic Epidemiology. There he developed and applied novel bioinformatical approaches for identifying genomic factors influencing lung, breast, head and neck, colon and brain cancer development. In 1994 he received his first NIH R01 to develop model-free linkage analysis methods and develop software to support these methods. He has subsequently received several other NIH grants as PI as well as Co-Investigator that have supported the development of new statistical methods to understand the interplay of genetic and environmental factors that cause lung cancer development. He wrote a book 'Forward-Time Population Genetics Simulations: Methods, Implementation, and Applications') with coauthors Dr. Bo Peng (at M.D. Anderson Cancer Center) and Dr. Marek Kimmel (at Rice) that describes approaches to simulating populations for genetic analyses. He also led studies that recruited and studied individuals with inherited risk for lung, colon and breast cancer. In 2004, in collaboration with Dr. Joan Bailey-Wilson and others, he identified a region of chromosome 6q23-25 that harbors a locus greatly increasing lung cancer risk, and showed in 2010 that this locus identifies individuals exquisitely sensitive to tobacco smoke. This collaboration led to the discovery that mutations in Park2 increase lung cancer risk. In 2008, he led large genetic studies that identified common variants in CHRNA5 (PMID 20554942 cited 1032 times) that have substantial impact on both lung cancer risk and smoking behavior, making it more difficult for smokers to quit. Dr. Amos led an ACS funded grant to study Peutz-Jeghers syndrome a rare condition that causes greatly increased risk for breast, colon and pancreatic cancers with most cases carrying mutations in STK11. He also lead the biostatistics and bioinformatics core for Dr. Louise Strong's P01 'A mutational model for Childhood Cancers' which led to the development of novel approaches for statistical and bioinformatical analysis to identify modifiers of risk for cancer. He also led several other bioinformatical and supported database development for several large projects including the Human Pedigree Analysis Resource core of the M.D. Anderson Cancer Center Support Grant, database development for the Gliogene Consortium, led by Dr. Melissa Bondy to identify genetic factors for familial brain cancers and Bioinformatics leader for the Texas Cancer Genetics Consortium which brought together investigators from UT Southwestern, UT San Antonio, UT M.D. Anderson Cancer Center and the Baylor College of Medicine to identify high risk families with cancer for whom targeted prevention and interventions would be effective. In 2012, Dr. Amos moved to the Geisel School of Medicine at Dartmouth College where he became the inaugural Chair for the Department of Biomedical Data Science, which includes Divisions of Biostatistics, Biomedical Informatics and Behavioral Studies. The Department grew under his leadership to 24 faculty members and about 80 staff. He also heads the Center of Genomic Medicine and became the Norris Cotton Cancer Center's Associate Director for Population Studies. Dr. Amos continued the work to identify and characterize genetic factors influencing lung cancer risk. He led an international team that studied over 50,000 individuals and identified uncommon mutations in BRCA2 that confer a 250% higher risk for developing squamous lung cancer. Dr. Amos is leading an international collaboration entitled 'Transdisciplinary Research in Cancer of the Lung' that had been supported by a U19 award from the NCI, which integrates genetic studies from international sites for discovery and epidemiological analysis of lung cancer risk. Work being performed by this consortium has been organized into a P01 submission that recently was approved for funding at the NCI with an expected start date of June 1, 2017. Dr. Amos moved to the Baylor College of Medicine on November 1, 2017 where he is the Associate Director for Quantitative Research and the Director of the Institute for Clinical and Translational Research. In addition to lung cancer, Dr. Amos has been involved in cutting edge research in other malignancies. He led the OncoArray Consortium that recently completed genotyping of about 500,000 individuals using a customized array developed with Illumina that comprises 500,000 markers. It was developed to decipher the genetic architecture of common cancers including prostate, colon, breast and ovarian cancers. Managing population-based analysis of this very large study required the development of new analytical approaches for characterizing the ethnic origin of participants to avoid confounding and the approach (published in BMC Bioinformatics). Results of studies using this array have been published in Nature Genetics for Head and Neck, Glioma (led by Dr. Melissa Bondy at the Baylor College of Medicine), and Ovarian Cancer, and there are additional accepted papers forthcoming in Nature and Nature Genetics. These papers have revealed the genetic architectures and more novel variants influencing Lung cancer, and ER+ and ER- breast cancer. Since 2014, Dr. Amos has been collaborating with Drs. Hashem El-Serag at Baylor College of Medicine and Manal Hassan at the M.D. Anderson Cancer Center in the Hepatobiliary Cancer Consortium which brings together North American Investigators to understand its environmental and genetic etiologies. This research has established a national consortium to identify genetic and environmental factors contributing to the epidemic of hepatobiliary cancer. Dr. Amos leads the design and analytical team responsibilities for the consortium. At Dartmouth, Dr. Amos co-leads the New Hampshire Colonoscopy Registry. Currently, he is serving at the interim Director of the Norris Cotton Cancer Center (NCCC), an NCI-designated cancer center. He leads the Center for Genomic Medicine, which was developed in collaboration with leaders in Pathology to develop approaches for routine sequencing for cancer NCCC patients. These data have been integrated with the electronic medical record, and are being used to identify clinical characteristics of patients associated with carriage of actionable mutations. Dr. Amos is also leader in cancer research mentoring. He is director of a Center of Biomedical Research Excellence grant (P20) 'Quantitative Biomedical Research Institute' that mentors junior faculty toward their initial award of an R01, and supports bioinformatics and personalized medicine at Dartmouth College and surrounding institutions in New Hampshire, Maine and Vermont. Dr. Amos serves as leader of the Biostatistics Epidemiology and Research Design component of the Clinical and Translational Institute at Dartmouth College, and has been directing the biomedical informatics team. Finally, Dr. Amos is leading a T32 training grant funded by the Knowledge to Big Data initiative for training graduate students in biomedical data sciences. Dr. Amos's expertise is recognized nationally and internationally. Dr. Amos became the President of the International Genetic Epidemiology Society in 2002, and served as its Secretary/Treasurer from 2007 to 2012. He served on the board of external scientific advisors for the Centre Etude Polymorphism Humain from 2007-2014. He was elected as a fellow of the American Association for the Advancement of Science in 2012. He currently serves on the Board of Scientific Counselors for the National Institute of Environmental Health Sciences. He completed a term as reviewer for the Access Committee for the Center for Inherited Disease Research from 2007-2011. He has also served as a reviewer for NIH, Cancer Research UK, and Canadian Institute for Health Research and numerous other panels. He has served or is serving as an associate editor for the American Journal of Human Genetics, Genes and Immunity, Genetic Epidemiology and Human and Molecular Genetics, and as a statistical editor for the Journal of the National Cancer Institute.
                                                            • Linnea Baudhuin, PhD, DABMG
                                                              Co-director, Pharmacogenomics and Genetics Laboratory, Co-director, Cardiovascular Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic
                                                              Biography
                                                                Dr. Baudhuin is Assistant Professor of Laboratory Medicine and Pathology, with a joint appointment in the Department of Medical Genetics, at the Mayo Clinic in Rochester, MN. Dr. Baudhuin is a co-director of molecular genetics, pharmacogenetics, and cardiovascular testing laboratories at the Mayo Clinic. Dr. Baudhuin received her Ph.D. in Clinical Chemistry from Cleveland State University (in conjunction with the Cleveland Clinic) and followed that up with fellowship training in Clinical Chemistry and Clinical Molecular Genetics at the Mayo Clinic. Dr. Baudhuin is board certified in Clinical Molecular Genetics by the American Board of Medical Genetics. Dr. Baudhuin's research interests lie primarily in the areas of cardiovascular-related genetics and pharmacogenetics. Dr. Baudhuin was the recipient of the 2011 Outstanding Scientific Achievements by a Young Investigator (American Association for Clinical Chemistry); the 2010 Clinical Laboratory Sciences Distinguished Author Award (American Society of Clinical Laboratory Science); and the 2006 George Grannis Award for Excellence in Research and Scientific Publication (National Academy of Clinical Biochemistry).
                                                              • Matthew Lebo, PhD, FACMG
                                                                Instructor of Pathology, BWH and Harvard Medical School, Assistant Laboratory Director and Senior IS Domain Specialist Laboratory for Molecular Medicine, Partners HealthCare Center for Perso